Christina T Muijs
Has grant
Associate professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Models project; developing prediction models for complications after neo-adjuvant chemoradiotherapy and resection
Open Date: 2023-02-01
Close Date:
Articles (18)
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Purpose: To present results from the trial radiotherapy quality assurance (RTQA) programme of the centres involved in the randomised phase-III PROton versus photon Therapy for esophageal Cancer – a Trimodality strategy (PROTECT)-trial, investigating the clinical effect of proton therapy (PT) vs. photon therapy (XT) for patients with oesophageal cancer. Materials and methods: The pre-trial RTQA programme consists of benchmark target and organ at risk (OAR) delineations as well as treatment planning cases, a facility questionnaire and beam output audits. Continuous on-trial RTQA with individual case review (ICR) of the first two patients and every fifth patient at each participating site is performed. Patient-specific QA is mandatory for all patients. On-site visits are scheduled after the inclusion of the first two patients at two associated PT and XT sites. Workshops are arranged annually for all PROTECT participants. Results: Fifteen PT/XT sites are enrolled in the trial RTQA programme. Of these, eight PT/XT sites have completed the entire pre-trial RTQA programme. Three sites are actively including patients in the trial. On-trial ICR was performed for 22 patients. For the delineation of targets and OARs, six major and 11 minor variations were reported, and for six patients, there were no remarks. One major and four minor variations were reported for the treatment plans. Three site visits and two annual workshops were completed. Interpretation: A comprehensive RTQA programme was implemented for the PROTECT phase III trial. All centres adhered to guidelines for pre-trial QA. For on-trial QA, major variations were primarily seen for target delineations (< 30%), and no treatment plans required re-optimisation.
Year:
2025
Year:
2025
Purpose Medical imaging is crucial in modern radiotherapy, aiding diagnosis, treatment planning, and monitoring. The development of synthetic imaging techniques, particularly synthetic computed tomography (sCT), continues to attract interest in radiotherapy. The SynthRAD2025 dataset and the accompanying SynthRAD2025 Grand Challenge aim to stimulate advancements in synthetic CT generation algorithms by providing a platform for comprehensive evaluation and benchmarking of synthetic CT generation algorithms based on cone‐beam CTs (CBCT) and magnetic resonance images (MRI). Acquisition and validation methods The dataset comprises 2362 cases, including 890 MRI‐CT pairs and 1472 CBCT‐CT pairs of head‐and‐neck, thoracic, and abdominal cancer patients treated at five European university medical centers [UMC Groningen, UMC Utrecht, Radboud UMC (Netherlands), LMU University Hospital Munich, and University Hospital of Cologne (Germany)]. Images were acquired using a wide range of acquisition protocols and scanners. Pre‐processing, including rigid and deformable image registration methods, was performed to ensure high‐quality image datasets and alignment between modalities. Extensive quality assurance was performed to validate image consistency and usability. Data format and usage notes All imaging data is provided using the MetaImage (.mha) file format, ensuring compatibility with common medical image processing tools. Metadata, including acquisition parameters and registration details, is available in structured comma‐separated value (CSV) files. To ensure dataset integrity, SynthRAD2025 is split into training (65%), validation (10%), and test (25%) sets. The dataset is accessible through https://doi.org/10.5281/zenodo.14918088 under the SynthRAD2025 collection. Potential applications This dataset enables benchmarking and development of synthetic imaging techniques for radiotherapy applications. Potential use cases include sCT generation for MRI‐only and MR‐guided photon and proton radiotherapy, CBCT‐based dose calculations, and adaptive radiotherapy workflows. By incorporating data from diverse acquisition settings, SynthRAD2025 supports the advancement of robust and generalizable image synthesis algorithms for clinical implementation, ultimately promoting personalized cancer care and improving adaptive radiotherapy workflows.
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Collaborators (19)
Elke Van Daele
Ghent University Hospital
Lisanne van Dijk
Associate professor & Technical physician
University Medical Center Groningen
Arturs Meijers
Head of clinical medical physics
Paul Scherrer Institut
Niklas Wahl
Research Group Leader
Deutsches Krebsforschungszentrum
Matthias Guckenberger
Chairman
University Hospital of Zurich
Nanna Maria Sijtsema
University Medical Center Groningen
Hanneke W. M. van Laarhoven
-
John H. Maduro
Scientific Staff
University Medical Center Groningen
Hanna Rahbek Mortensen
Associate Professor
Aarhus University
Alessio Giuseppe Morganti
ALMA MATER STUDIORUM UNIVERSITY OF BOLOGNA
Jacco de Haan
University Medical Center Groningen
Camiel Rosman
Radboud University Medical Center
Erik Korevaar
University Medical Center Groningen
Johannes A. Langendijk
Scientific Staff
University Medical Center Groningen
Ditte Sloth Møller
Head of Medical Physics
Aarhus University
Arjen van der Schaaf
Scientific Staff
University Medical Center Groningen
L. Hoffmann
VIP, Associate Professor
Aarhus University Hospital
Anna Dorothea Wagner
Senior lecturer, consultant and head of the gastrointestinal cancer outpatient clinic
Lausanne University Hospital
Per Pfeiffer
University of Southern Denmark
Make your next move.
Prepare your application
Review drafts before you send them.